Clearside Biomedical (NASDAQ:CLSD) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent that will provide intellectual property protection for methods of treating posterior ocular disorders by non-surgically administering axitinib to the suprachoroidal space of the eye.
This patent represents one in a series of filings protecting the use of the suprachoroidal space as a location in the eye to dose drug that provides for higher bioavailability to target retinal and choroidal diseases, regardless of the method of administration.
In 2016, Clearside selected axitinib as the lead compound for its development program for the treatment of wet AMD through suprachoroidal administration. In preclinical models, axitinib had a long drug half-life and high bioavailability in the tissues of the back of the eye. Axitinib targets all vascular endothelial growth factor receptors, in addition to other key receptors involved in angiogenesis.
“This is the seventh patent allowance in the U.S. related to our proprietary approach for the treatment of blinding diseases,” president and CEO, Daniel White, said in a statement. “Our IP estate provides important protection for opportunities to provide treatment for eye diseases via suprachoroidal drug administration.”